Recombinant Human VEGF-C

Catalog Number: 2179-VC/CF

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived Thr103-Arg227, with a C-terminal 10-His tag Accession # P49767
N-terminal Sequence Analysis	Thr103
Predicted Molecular Mass	15.5 kDa

SPECIFICATIONS

SDS-PAGE	21 kDa, reducing conditions
Activity	Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. *et al.* (1999) Proc. Natl. Acad. Sci. USA **96**:9671. The ED_{50} for this effect is 0.2-0.8 µg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF R3/Flt-4 Fc Chimera (Catalog # 349-F4) binds Recombinant Human VEGF-C with an apparent K_d <15 nM.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in HCl. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References:

1. Chen, J.-C. *et al.* (2013) Int. J. Mol. Sci. **14**:88.
2. Joukov, V. *et al.* (1996) EMBO J. **15**:290.
3. Kukk, E. *et al.* (1996) Development **122**:3829.
4. Joukov, V. *et al.* (1997) EMBO J. **16**:3898.
5. Karkkainen, M. *et al.* (2004) Nat. Immunol. **5**:74.
6. Jeltsch, M. *et al.* (1997) Science **276**:1423.
7. Makinen, T. *et al.* (2001) Nat. Med. **7**:199.
8. Laakkonen, P. *et al.* (2007) Cancer Res. **67**:593.
9. Hoshida, T. *et al.* (2006) Cancer Res. **66**:8065.
10. Mandriota, S.J. *et al.* (2001) EMBO J. **20**:672.
11. Skobe, M. *et al.* (2001) Nat. Med. **7**:192.
12. Padera, T.P. *et al.* (2002) Science **296**:1883.
13. Tammela, T. *et al.* (2008) Nature **454**:656.
14. Cao, Y. *et al.* (1998) Proc. Natl. Acad. Sci. **95**:14389.

bio-techne®
Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449